American Society of Hematology

Figure 4.

$Figure 4. Expression of PDGFR-β on CD31/VEGFR-2–positive cells at different time points. (A) Semiquantitative PCR analysis of VE-cadherin (VE-cad), αfetoprotein (AFP), PDGFR-β, and β–actin levels in immunopurified CD31/VEGFR-2–expressing cells and in the flow-through fractions derived from embryoid bodies cultured for 6, 8, or 14 days in the presence or absence of PDGF-BB. (B) Validation by FACS analyses of CD31 and VEGFR-2 expression in immunopurified fractions derived from embryoid bodies cultured for 6 days in the presence or absence of PDGF-BB. Unstained cells served as a control. (C) Real-time PCR analysis of PDGFR-β expression in CD31/VEGFR-2–positive cells and in flow-through and of VEGFR-2 expression in the CD31/VEGFR-2–positive cells derived from embryoid bodies treated or not treated with PDGF-BB, as described in panel A. Results are given as mean ± SD fold induction compared with basal of 3 separate experiments. *P < .05; **P < .008; ***P < .001.$

Expression of PDGFR-β on CD31/VEGFR-2–positive cells at different time points. (A) Semiquantitative PCR analysis of VE-cadherin (VE-cad), αfetoprotein (AFP), PDGFR-β, and β–actin levels in immunopurified CD31/VEGFR-2–expressing cells and in the flow-through fractions derived from embryoid bodies cultured for 6, 8, or 14 days in the presence or absence of PDGF-BB. (B) Validation by FACS analyses of CD31 and VEGFR-2 expression in immunopurified fractions derived from embryoid bodies cultured for 6 days in the presence or absence of PDGF-BB. Unstained cells served as a control. (C) Real-time PCR analysis of PDGFR-β expression in CD31/VEGFR-2–positive cells and in flow-through and of VEGFR-2 expression in the CD31/VEGFR-2–positive cells derived from embryoid bodies treated or not treated with PDGF-BB, as described in panel A. Results are given as mean ± SD fold induction compared with basal of 3 separate experiments. *P < .05; **P < .008; ***P < .001.

This Feature Is Available To Subscribers Only